Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kinesia-360 Wearable for Neupro Titration in Parkinson's
NCT03103919Phase 4Completed
- Sponsor
- UCB
- Start
- Mar 2017
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of rotigotine in Parkinson's disease (PD) (2 arms), sponsored by UCB. Primary endpoints: Unified Parkinson's Disease Rating Scale Part III Motor Score at 12 weeks, Kinesia-ONE Variable: Finger Tapping Speed Score at 12 weeks and 12 more. Started Mar 2017; status: completed.
02
Drugs
rotigotine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT03103919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03103919.